ASH 2023 | CD33-TIM3 dual CAR T-cells enhance specificity of AML treatment
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, discusses the three main approaches and concepts within CAR T-cell therapy, highlighting her work on CD33 and TIM3 dual-targeting CAR T-cells. These cells are engineered to target only those cells expressing both the CD33 and TIM3 antigens, leading to an increase in specificity when treating acute myeloid leukemia (AML) and allowing for the treatment of patients without the need for allogeneic stem cell transplantation. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Pfizer, Takeda, Ichnos Sciences, AvenCell, Incyte Biosciences, Molecular Partners, AbbVie, Autolus, advesya (CanCell Therapeutics), Genmab US, Interius BioTherapeutics, Nektar Therapeutics, Orbital Therapeutics, Sanofi, Scare
Honoraria: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Pfizer, Takeda, Ichnos Sciences, AvenCell, Incyte Biosciences, Molecular Partners, AbbVie, Autolus, advesya (CanCell Therapeutics), Genmab US, Interius BioTherapeutics, Nektar Therapeutics, Orbital Therapeutics, Sanofi, Scare
Research Funding: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Seagen, Takeda, Molecular Partners
Speakers Bureau: Janssen, Roche, BMS/Celgene, Novartis, Gilead/Kite, Pfizer, AstraZeneca, GSK, LAWG, Springer Healthcare
Travel Support: Roche, Gilead/Kite, Pfizer
